To identify potential biomarkers predictive of durable clinical response and further elucidate the molecular features of AFP-G/GEJ adenocarcinoma, targeted exome next-generation sequencing (NGS) and multiplex immunofluorescence (mIF) were performed (Fig. 3a). This evidence concerns the gene AFP and adenocarcinoma.